Announcements Trials
Browse Landscape

Phase

Phase 2 40Phase 1 20Phase 3 18Phase 1/2 7Phase 4 3Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Lymphoid 2Plasma cell 1

Conditions

Lymphoma, Large-Cell, Anaplastic 2Granuloma, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1ALK or ROS1-positive NSCLC 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Crizotinib × Clear all
NCT05160922 2026-03-30

Crizotinib Continuation Clinical Study

Pfizer

Phase 4 Active not recruiting
27 enrolled
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT03672643 2024-11-08

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Pfizer

Phase 4 Terminated
41 enrolled 9 charts
Thoracic

ALK or ROS1-positive NSCLC

NCT02487316 2016-12-30

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Peking University

Phase 4 Withdrawn
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡